Was the GlaxoSmithKline FCPA resolution a missed opportunity?
Tom Fox questions whether U.S. regulators missed a chance to illustrate how they would give credit for anti-corruption prosecutions done by other governments in the case of GlaxoSmithKline’s China subsidiary’s recent FCPA resolution.
Related articles
-
WebcastSept 23 | Decoding DOJ’s Recent Guidance on FCPA Enforcement
Join this timely and practical webinar as we break down the DOJ’s latest FCPA guidance and explore what these developments mean for compliance programs in the real world.
-
News BriefDOJ, SEC charge owner of Pennsylvania companies of running $770M Ponzi scheme
The majority owner of a Pennsylvania investment firm faces 100 years of prison time and huge fines for allegedly running a $770 million Ponzi scheme centered on an ATM company he also owned.
-
ArticleChinese money-laundering networks moved $312B in dirty money through the U.S.
Suspicious activity reports filed by U.S. financial institutions show that Mexican drug cartels and human traffickers are laundering dirty funds through Chinese money laundering networks (CMLNs) operating in the United States, according to the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN).